ADORA2A and amyotrophic lateral sclerosis: This discrepancy may reflect fundamental differences between ALS models: SOD1-G93A mice exhibit a transgene-driven disease course with later symptom onset (typically around postnatal day 90) and progressive neurodegeneration [63], along with a marked downregulation of adenosine A2A-receptors in the spinal cord [52].